Home        Sitemap        Contact us 
Rheumatoid Arthritis (RA)
You are in: » Pipeline  » Targeted Therapeutics  » Inflammation/Autoimmune  » Rheumatoid Arthritis (RA)
The pharmaceutical/Biotechnology industries over the decade extensively exploring the novel autoimmune disease causing targets for RA, Psoriasis, Lupus, Multiple Sclerosis, Inflammatory bowl and Asthma diseases. More than 200 candidates currently in the clinical development stage and due to their insufficiency of the standard of care, the area remains beginning process in search for novel and improved therapeutics. Over the last five years several promising novel small molecule therapeutic agents alter intracellular signalling pathways mediate cell responses have been developed. Most of these agents inhibit the protein kinases such as Mitogen-Activated Protein Kinases (MAPKs), non-receptor Spleen Tyrosine Kinase (Syk) and Janus Kinases (JAKs). More than 3050% of patients who do not respond or have an appropriate clinical response to the current drugs and require long-term treatment.

Arrien identified a very potent selective ARN-4079 a small molecule ATP competitive kinase inhibitor for chronic and debilitating condition of RA.
Arrien Pharmaceuticals is developing ARN-4079, a novel oral and highly selective irreversible kinase inhibitors selectively targeting JAK3 and ITK kinases, which play vital role in several diseases including Rheumatoid arthritis. ARN-4079 is nominated candidate and is currently being evaluated in pre-clinical cellular and CIA animal models and showed promising efficacy over the some of the approved or experimental lead agents.
Copyright © 2011, Arrien Pharmaceuticals, LLC. All rights reserved.